Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

BACKGROUND: Tumor necrosis factor superfamily member 14 (TNFRSF14)/herpes virus entry mediator (HVEM) is the ligand for B and T lymphocyte attenuator (BTLA) and CD160-negative immune co-signaling molecules as well as viral proteins. Its expression is dysregulated with an overexpression in tumors and...

Descripción completa

Detalles Bibliográficos
Autores principales: Demerlé, Clémence, Gorvel, Laurent, Mello, Marielle, Pastor, Sonia, Degos, Clara, Zarubica, Ana, Angelis, Fabien, Fiore, Frédéric, Nunes, Jacques A, Malissen, Bernard, Greillier, Laurent, Guittard, Geoffrey, Luche, Hervé, Barlesi, Fabrice, Olive, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231015/
https://www.ncbi.nlm.nih.gov/pubmed/37230538
http://dx.doi.org/10.1136/jitc-2022-006348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231015/
https://www.ncbi.nlm.nih.gov/pubmed/37230538
http://dx.doi.org/10.1136/jitc-2022-006348

Ejemplares similares